Healthcare Industry News: HSMN NewsFeed
News Release - May 16, 2017
Boston Scientific Closes Symetis AcquisitionAcquisition Expands Company's Structural Heart Portfolio; Increases Offerings for the Treatment of Patients with Valvular Heart Disease
MARLBOROUGH, Mass., May 16, 2017 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) devices.
With the completion of the acquisition, Boston Scientific will immediately begin selling the ACURATE TA™ and ACURATE neo™/TF™ valve* systems in Europe and in other geographies outside of the United States, and Symetis will become part of the Boston Scientific Interventional Cardiology division.
The two organizations announced a definitive agreement on March 30, 2017 for Boston Scientific to acquire the Symetis business for $435 million in cash.
"Adding the ACURATE family of valve products to our structural heart portfolio presents us with the opportunity to provide two distinctly different but complementary TAVI platforms enabling implanting physicians and hospitals to treat the broadest range of patients and aortic valve anatomies," said Ian Meredith, M.D., executive vice president and global chief medical officer, Boston Scientific. "This valve offering, along with our left atrial appendage closure device, uniquely position us to advance structural heart solutions for patients while fueling continued growth for the company."
As with the company's cornerstone LOTUS Valve System** platform, the ACURATE valves are designed to treat patients suffering from severe and symptomatic aortic valve stenosis, who are considered at high risk for surgical valve replacement. Instead of open heart surgery, the replacement valve is delivered via a transcatheter percutaneous delivery system. The ACURATE platform is recognized for its ease of use during valve implantation.
Results for the ACURATE neo/TF valve in the SAVI-TF Registry will be presented today as a late breaking clinical trial at the annual EuroPCR Scientific Congress in Paris. This European post-market study assesses the primary endpoint of all-cause mortality at 30 days as well as VARC-2*** clinical endpoints through one year in 1,000 patients.
Boston Scientific expects to continue the development of the ACURATE neo/AS**** next-generation valve system that is currently in a clinical trial intended to support a future CE mark application.
On an adjusted basis, the transaction is expected to be immaterial in 2017, slightly accretive in 2018, and increasingly accretive thereafter. The transaction is expected to be less accretive (or slightly dilutive, as the case may be) on a GAAP basis, due to amortization expense and transaction and integration costs.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
* The ACURATE TA™ and ACURATE neo/TF™ valve systems are not available for use or sale in the US.
** The LOTUS™ valve is currently not available for use or sale.
*** Valve Academic Research Consortium-2 (VARC-2) criteria are standardized endpoints for TAVI outcomes.
**** The ACURATE neo/AS valve system is not available for use or sale.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding the closing of the acquisition, the financial and business impact of the transaction, product launches and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; the closing and integration of acquisitions; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
Use of Non-GAAP Financial Measures
To supplement our consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures including adjusted earnings per share. Adjusted earnings per share excludes goodwill and intangible asset impairment charges; acquisition-, divestiture-, litigation- and restructuring-related charges and credits; certain discrete tax items and amortization expense. Non-GAAP measures such as adjusted earnings per share are not in accordance with generally accepted accounting principles in the United States. The GAAP financial measure most directly comparable to adjusted earnings per share is GAAP earnings per share. The difference between our estimated impact of the acquisition on our GAAP and adjusted earnings per share relates to amortization expense on acquired intangible assets and acquisition-related net charges, which primarily include exit costs and other fees. These amounts are excluded by the Company for purposes of measuring adjusted earnings per share. Management uses adjusted earnings per share along with other supplemental non-GAAP measures to evaluate performance period.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsApexigen Expands Leadership Team With Appointment Of Frances Rena Bahjat, Ph.D. Vice President, Discovery Research
FDA Approves Aimovig(TM) (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
Award-Winning Olympus Brings a "Full Circle" Urology Offering to AUA